WithdrawnPhase 1/2

Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases

Stopped: According to sponsor strategy

0Started 2023-01-18

Plain-language summary

A Phase I/II Study of LM-305 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Subjects who are fully informed of the purpose, nature, method and possible adverse reactions of the study, and are willing to participate in the study and sign the informed consent form (ICF) prior to any procedure.
. Aged ≥18 years old when sign the ICF, male or female.
. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1。
. Life expectancy ≥ 6 months.
. Subjects must show appropriate organ and marrow function in laboratory examinations

Exclusion criteria

. A history of other malignant tumors than multiple myeloma within 3 years prior to first dosing
. Subjects who have severe cardiovascular disease。
. Use of any live attenuated vaccines within 28 da ys prior to 1st dosing of IMP.
. Child-bearing potential female who have positive results in pregnancy test or are lactating.
. Subject who is judged as not eligible to participate in this study by the investigator.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Dose limiting toxicity (DLT)

Timeframe: Cycle 1 of each cohort. Duration of one cycle is 21 days

Adverse Events (AE) and Serious Adverse Events (SAE)

Timeframe: From signing the informed consent form (ICF) until 28 days after end of treatment (EOT) or accept other anti-cancer therapy

Trial details

NCT IDNCT05647512

SponsorLaNova Medicines Limited

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-12-01

View on ClinicalTrials.gov More Relapsed or Refractory Multiple Myeloma trials